Provided by Tiger Trade Technology Pte. Ltd.

Sub-New Stocks

318.405
-1.445-0.45%
Number of Gainers:22
Number of Losers:29
Number of Flat:8
PE:- -
High:320.084
Open:319.660
Low:313.128
Close:319.849
Volume:79.98M
Turnover:3.36B
Market Cap:753.85B
Float Cap:672.42B

Loading ...

Asia-Pacific Emerging Economies Shifting Toward Industrial Upgrades, Fueling Demand for Semiconductors and More

Deep News
·
Sep 03

NAYUKI's August Buyback: 3.275 Million Shares Repurchased and Designated as Treasury Stock

Deep News
·
Sep 03

ZYLOXTB (02190) Allocates HK$1.12 Million for Share Buyback on September 3

Stock News
·
Sep 03

Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Buyback

Reuters
·
Sep 03

HUTCHMED Surges 14% on $1.295 Billion Licensing Deal with GSK for Novel Dual-Targeting Cancer Therapy

Deep News
·
Sep 03

Asian Market Selloff Triggered by Yen Rally While Precious Metals Rebound Lifts Mining Sector

Stock News
·
Sep 03

Hong Kong Stocks Fall on Thursday, Amid Bond Selloff, Rate Fears; HUTCHMED Jumps 14%

MT Newswires Live
·
Sep 03

UK Stocks-Factors to Watch on September 3

Reuters
·
Sep 03

HK Stock Alert: Keymed Bio Surges Over 3% on Landmark Licensing Deal with Aeira

Stock News
·
Sep 03

Hutchmed China Ltd - Hutchmed Licenses Kras-Egfr-Antibody to GSK

THOMSON REUTERS
·
Sep 03

港股动态:携程股价重挫逾4%,增长减速预期与多重宏观压力引发市场忧虑

Stock News
·
Sep 03

Keymed Biosciences Climbs on Licensing Deal with Aeira Pte

Reuters
·
Sep 03

Hutchmed (China) Signs Exclusive Licensing Deal with GSK for Investigational Cancer Drug

Reuters
·
Sep 03

Hutchmed (China) - to Start Global Phase 1 Development Program in H2 2026

THOMSON REUTERS
·
Sep 03

Hutchmed Licenses KRAS-EGFR Antibody Conjugate HMPL-A830 to GSK for USD 110 Million Upfront

Reuters
·
Sep 03

Hutchmed (China) - Agreement Includes $110 Mln Upfront, up to $1.30 Bln in Milestones, Plus Royalties

THOMSON REUTERS
·
Sep 03

Hutchmed Announces Licensing Agreement with GSK for Kras-Egfr-Antibody Conjugate Cancer Therapy

THOMSON REUTERS
·
Sep 03

Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets

MT Newswires
·
Sep 03

Sanxun Holdings Group Announces Winding up Petition

Reuters
·
Sep 02

Keymed Biosciences Licenses Stapokibart Marketing, Sales Rights in 18 Southeast and Central Asia Markets to Aeira

Reuters
·
Sep 02